REVIEW

West Nile Virus Infection in the Central Nervous System

[version 1; peer review: 3 approved]

Evandro R. Winkelmann¹, Huanle Luo¹, Tian Wang ^{1,2}

¹Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas, 77555, USA

²Department of Pathology, University of Texas Medical Branch, Galveston, Texas, 77555, USA

V1 First published: 26 Jan 2016, 5(F1000 Faculty Rev):105
<https://doi.org/10.12688/f1000research.7404.1>

Latest published: 26 Jan 2016, 5(F1000 Faculty Rev):105
<https://doi.org/10.12688/f1000research.7404.1>

Abstract

West Nile virus (WNV), a neurotropic single-stranded flavivirus has been the leading cause of arboviral encephalitis worldwide. Up to 50% of WNV convalescent patients in the United States were reported to have long-term neurological sequelae. Neither antiviral drugs nor vaccines are available for humans. Animal models have been used to investigate WNV pathogenesis and host immune response in humans. In this review, we will discuss recent findings from studies in animal models of WNV infection, and provide new insights on WNV pathogenesis and WNV-induced host immunity in the central nervous system.

Keywords

West Nile Virus , west nile virus infection in central nervous system , central nervous system infection , flavivirus , arboviral encephalitis

Open Peer Review

Approval Status

	1	2	3
version 1 26 Jan 2016

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Sebastian Ulbert**, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany
2. **Giorgio Palù**, University of Padova, Padova, Italy
3. **Anna Papa**, Aristotle University of Thessaloniki, Thessaloniki, Greece

Any comments on the article can be found at the end of the article.

Corresponding author: Tian Wang (ti1wang@utmb.edu)

Competing interests: The authors declare that they have no competing interests.

Grant information: This work was supported in part by National Institutes of Health grant R01 AI099123 (TW).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2016 Winkelmann ER *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Winkelmann ER, Luo H and Wang T. **West Nile Virus Infection in the Central Nervous System [version 1; peer review: 3 approved]** F1000Research 2016, 5(F1000 Faculty Rev):105 <https://doi.org/10.12688/f1000research.7404.1>

First published: 26 Jan 2016, 5(F1000 Faculty Rev):105 <https://doi.org/10.12688/f1000research.7404.1>

Introduction

West Nile virus (WNV), a mosquito-borne, single-stranded, positive-sense flavivirus, has been the leading cause of viral encephalitis in the US for more than a decade. The virus was originally isolated from Uganda in 1937, later caused epidemic outbreaks in Asia, Europe, and Australia, and was introduced into the US in 1999¹. Human infection results mostly from mosquito bites, blood transfusion, organ transplantation, or occupational exposure^{2,3}. In addition, WNV transmission through breastfeeding and *in utero* exposure is possible, although recent evidence suggests that the risk is very low^{4–7}. About 80% of human infections with WNV are asymptomatic. The features of acute illness range from West Nile fever, to neuroinvasive conditions, including meningitis, encephalitis, acute flaccid paralysis, and death⁸. Up to 50% of convalescent patients with WNV have been reported to have long-term neurological sequelae or develop chronic kidney diseases, or both^{9–17}. Although serologic and organ screening may reduce the risk of WNV infection through blood transfusion and organ transplantation^{18–20}, there is no specific therapeutic agent for treatment of WNV infection, and an approved vaccine is not currently available for humans.

Animal models, which recapitulate WNV-induced neurological diseases in humans, have been effective *in vivo* experimental models to investigate WNV pathogenesis and host immune response^{21–23}. In this review, we discuss recent findings from studies in animal models of WNV infection and provide new insights on WNV pathogenesis and virus-induced host immunity in the central nervous system (CNS).

West Nile virus entry into the central nervous system

The natural transmission of WNV in humans occurs through mosquito bites²⁴. Keratinocytes and Langerhans cells (LCs) are the initial target cells where the virus is naturally deposited. WNV infection in keratinocytes induces innate cytokine responses mediated by Toll-like receptor (TLR) 7, which further promotes LC migration from the epidermis and accumulation in the local

draining lymph nodes, where the virus is amplified before dissemination to kidney, spleen, and other visceral organs^{25–27}. Following a systemic infection, WNV crosses the blood-brain barrier (BBB) after a brief viremia and ultimately invades the CNS²⁸.

The development of WNV encephalitis is correlated with the ability of the virus to gain access to the CNS (neuroinvasiveness). At present, the mechanisms by which WNV enters the brain are not well understood. As a higher viral burden in serum usually correlates with earlier viral entry into the brain, it has been suggested that WNV infects the CNS in part via hematogenous spread²⁹. The BBB is a complex structure that is composed of the tight endothelium formed by endothelial cells through tight junctions and smooth muscle cells surrounded by a layer of astrocytic foot processes^{30,31}. Systemic WNV replication-induced innate cytokine responses are known to control BBB integrity (Table 1). Pro-inflammatory cytokines, including tumor necrosis factor- α (TNF- α), interleukin-1 beta (IL-1 β), and macrophage migration inhibitory factor (MIF), contribute to the disruption of the BBB^{32–34}. In addition, matrix metalloproteinase 9 (MMP9), which is upregulated upon WNV infection in both the periphery and mouse brain, facilitates WNV entry into the brain by enhancing BBB permeability³⁵. Semaphorin 7A (Sema7A), a potent stimulator of monocytes and neutrophils, acts upstream of the host inflammatory reaction during WNV infection. Following infection, Sema7A-deficient mice produced less TNF- α in the periphery and had a reduced BBB permeability compared with wild-type controls³⁶. In contrast to the effects of pro-inflammatory cytokines, both type I interferon (IFN) (IFN- α and IFN- β) and type III (IFN- λ) are implicated in promoting BBB integrity. Daniels *et al.* have recently demonstrated that type I IFNs play a direct role in endothelial permeability and tight junction formation via balanced activation of the small guanosine triphosphatases (GTPases) Rac1 and RhoA interactions and indirect suppression of the effects of TNF- α and IL-1 β ³³. The TAM receptors Tyro3, Axl, and Merck are receptor tyrosine kinases that dampen host innate immune responses upon interactions with their ligands

Table 1. Host factors modulate blood-brain barrier integrity.

Host factors	Effects on BBB integrity	References
Pro-inflammatory cytokines, including TNF- α , IL-1 β , and MIF	Disruption of the BBB	32–34
Matrix metalloproteinase 9	Enhancing BBB permeability	35
Semaphorin 7A	Enhancing BBB permeability by promoting TNF- α production	36
Type I IFNs (IFN- α and IFN- β)	Promoting BBB integrity via balanced activation of the small guanosine triphosphatase Rac1 and RhoA interactions and indirect suppression of the effects of TNF- α and IL-1 β	33
TAM receptors Tyro3, Axl, and Merck	Promote BBB integrity by synergizing type I IFNs	38
IFN- λ	Modulates tight junction protein localization in brain microvascular endothelial cells, which increases transendothelial electrical resistance and decreases virus movement across the BBB	39
CAMs, such as ICAM-1, VCAM-1, and E-selectin	Upregulation of CAM expression induces the adhesion and transendothelial migration of leukocytes across these cells	40,41

BBB, blood-brain barrier; CAM, Cell adhesion molecules; ICAM-1, intercellular adhesion molecule-1; IFN, interferon; IL-1 β , interleukin-1 beta; MIF, macrophage migration inhibitory factor; TNF- α , tumor necrosis factor- α ; VCAM-1, vascular cell adhesion molecule-1.

Gas6 and Protein S, which recognize phosphatidylserine on apoptotic cells³⁷. A recent study showed that activation of MERTK synergized with IFN- β to tighten cell junctions and prevent virus transit across brain microvascular endothelial (BMVE) cells. As a consequence, mice lacking MERTK or AXL (or both), but not TYRO3, exhibited greater vulnerability to infection with neuroinvasive WNV³⁸. In another study³⁹, mice lacking IFN- λ signaling were shown to have increased viral titers in the brain and spinal cord during WNV infection. This is not associated with a direct antiviral effect of IFN- λ in the CNS. Instead, IFN- λ signaling in BMVE cells modulates tight junction protein localization in a protein synthesis- and signal transducer and activator of transcription 1 (STAT1)-independent manner, which increases transendothelial electrical resistance and decreases virus movement across the BBB. Besides innate cytokines, upregulation of cell adhesion molecules (CAMs), such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), and E-selectin expression on WNV-infected BMVEs induces the adhesion and transendothelial migration of leukocytes across these cells^{40,41} (Table 1). Moreover, direct infection of BMVE cells facilitates the entry of cell-free virus into the CNS without disturbing the BBB, and an increase on CAM further assists the trafficking of WNV-infected immune cells into the CNS via a 'Trojan horse' mechanism, thereby contributing to WNV dissemination into the CNS and its associated pathology^{42–44}. Finally, infection of the olfactory neurons and consequent dissemination to the olfactory bulb and direct axonal retrograde transport of virus that has infected peripheral neurons have been postulated as the other mechanisms of WNV entry into the CNS^{45–47}.

The host has developed multiple strategies to limit virus dissemination in the periphery and prevent the trafficking of WNV across the BBB. First, WNV infection activates the signaling pathways of several pattern recognition receptors (PRRs), including TLRs 3 and 7 and RIG-I-like receptor (RLR), in order to boost innate immunity, culminating in the synthesis of antiviral cytokines, such as type I IFNs and pro-inflammatory cytokines^{34,48–50}. Type I IFNs and IFN-stimulating genes (ISGs) both participate in the control of viral infections and prevent WNV from invading the CNS^{51–54}. Next, innate immune cells such as $\gamma\delta$ T cells (in particular, the $V\gamma 1^+$ cell subpopulation) expand significantly during WNV infection and play a role in the early control of WNV dissemination mainly through the secretion of IFN- γ ^{55–57}. These cells are also involved in the regulation of adaptive immunity against WNV infection and persistence, presumably mediated by the crosstalk between $\gamma\delta$ T cells and dendritic cells (DCs), either via direct contact or indirectly through secreting molecules, to promote DC maturation and activation and ultimately to help T cell priming during WNV infection⁵⁸. TCR $\delta^{-/-}$ mice ($\gamma\delta$ T cell-deficient mice) were shown to have a numeric and functional reduction in memory T cell responses to WNV infection compared with wild-type mice⁵⁹. Furthermore, B cells and specific antibodies are critical in the control of disseminated WNV infection but are not sufficient to eliminate it from the host^{29,60–62}. In particular, induction of a specific, neutralizing IgM response early during infection limits viremia and dissemination into the CNS and protects the host against lethal infection²⁹. In addition, the complement system has been shown to control WNV infection, in part through its ability to induce a protective antibody response and by priming adaptive immune responses through

distinct mechanisms^{63,64}. $\alpha\beta$ T cells⁶¹ provide long-lasting protective immunity and contribute to host survival following WNV infection. Among them, CD4 $^{+}$ T cells respond vigorously in the periphery⁶⁵, whereas CD8 $^{+}$ T cell responses have been observed in both the spleen and brain following WNV infection⁶⁶. CD4 $^{+}$ T cells provide help for antibody responses and sustain WNV-specific CD8 $^{+}$ T cell responses in the tissues that enable viral clearance⁶⁷. CD8 $^{+}$ T cell responses are critical in clearing WNV infection from tissues and preventing viral persistence⁶⁸. Furthermore, higher levels of peripheral regulatory T cells (Tregs) after infection are known to protect against severe WNV disease in immunocompetent animals and humans⁶⁹. Tregs are also critical in generating a pool of WNV-specific memory T cells in the periphery⁷⁰. RLR-mediated innate signaling is involved in regulating adaptive immunity against pathogenic WNV. Mice deficient in mitochondrial antiviral signaling protein (MAVS), the adaptor protein for RLR signaling, were reported to exhibit lower neutralization ability of WNV-specific antibodies and increased numbers of virus-specific CD8 $^{+}$ T cells, with non-specific immune cell proliferation in the periphery⁷¹.

Aging is a known risk factor for WNV-induced encephalitis^{23,72,73}. The decline in immunity seen in the elderly is a significant contributor to the increased risk of infection. In an aged mouse model of WNV infection, $V\gamma 1^+$ cells displayed a slower, reduced response to WNV infection compared with those of young adult mice⁵⁷. Although the young adult CD4 $^{+}$ or CD8 $^{+}$ T cells readily protected immunodeficient mice upon WNV infection, T cells of either subset in aged mice were unable to provide WNV-specific protection⁷⁴. Furthermore, a recent study⁷⁵ reported that age-dependent cell-intrinsic and environmental defects in the draining lymph nodes result in delayed immune cell recruitment and antigen recognition by CD4 $^{+}$ T cells, leading to impaired IgM and IgG and increased susceptibility to WNV infection in old mice.

West Nile virus infection and West Nile virus-induced immune responses in the central nervous system

Once in the brain, WNV can infect and replicate in various types of CNS residential cells, including neurons, astrocytes, and microglial cells^{76,77}. In a recent study, by using a spinal cord slice culture (SCSC) model, CNS-resident cells were demonstrated to have the capacity to initiate a robust innate immune response against WNV infection in the absence of infiltrating inflammatory cells and systemic immune responses⁷⁶. CNS cells display differential susceptibility to WNV infection, dependent on their cell-intrinsic host defense programs and cellular activities (Table 2). The antiviral action of ISG-Ifit2 restricts WNV spread in the CNS, especially during the early stages of virus spread⁷⁸. Granule cell neurons (GCNs) of the cerebellum, which comprise the largest population of neurons in the brain, express high levels of genes associated with the host defense pathway, including a STAT1- and IFN-dependent signaling signature both at the basal level and after IFN- β treatment. These cells are less susceptible than cortical neurons to WNV replication⁷⁹. Multiple PRR pathways are involved in the induction of antiviral responses in neurons. IL-1 β production triggered by non-obese diabetic (NOD)-like receptor family pyrin domain containing 3 (NLRP3)-inflammasome suppressed WNV replication in neurons⁸⁰. Both myeloid differentiation primary response gene 88 (MyD88)- and TLR3-mediated innate signaling play protective

Table 2. Central nervous system cell types and West Nile virus-induced immune responses.

Cells	Immune induction or cellular activities, or both	Effects on host or cells
Neurons	WNV infection triggers IL-1 β , IFNs, IFN-stimulating genes, or chemokine production mediated via multiple pathogen recognition receptors, including non-obese diabetic-like receptor family pyrin domain containing 3 (NLRP3)-inflammasome, TLR3, myeloid differentiation primary response gene 88 (MyD88), and Caspase-12-dependent-RIG-I	Restrict WNV infection in the CNS or facilitate immune cells to cross blood-brain barrier and enter the CNS
Microglia	WNV infection triggers TLR3-mediated TNF- α , IL-6, and IFN- β responses	Restrict WNV infection in the CNS
Astrocytes	Inhibit high levels of furin-like protease activity	Restrict avirulent WNV infection in the CNS
Monocyte/Macrophage	Migration into the CNS via CCL2-, CCL7-, TLR7-, or IL-23-dependent pathways	Protective or detrimental?
Neutrophils	Recruitment into the CNS mediated by IL-22 and CXCR2	Control of viral infection at the late stage of infection
CD4 ⁺ T cells	Recruitment into the CNS, producing IFN- γ and IL-2, and regulation by IL-1R-dependent CD11c ⁺ cell response	Directly involved in viral clearance, or by sustaining WNV-specific CD8 ⁺ T-cell response in the CNS, or both
CD8 ⁺ T cells	Recruitment into the CNS; producing IFN- γ , or direct killing of infected cells through secretion of perforin and Fas/Fas ligand, or TNF-related apoptosis-inducing ligand (TRAIL)-dependent pathways; dependent on RIG-I-like receptor (RLR) signaling, and mediated by CXCR4 and IL-1 β	Control viral replication upon low-dose WNV challenge and induction of immunopathology in the CNS upon high-dose WNV infection

CNS, central nervous system; IFN, interferon; IL, interleukin; TLR, Toll-like receptor; TNF- α , tumor necrosis factor-alpha; WNV, West Nile virus.

roles against WNV infection, in part by inhibiting replication in subsets of neurons^{81,82}. Caspase-12 controls WNV infection in neurons by regulating E3 ubiquitin ligase TRIM25-mediated ubiquitination of RIG-I, which induces high levels of IFN responses⁸³. WNV also triggers production of TNF- α , IL-6, and IFN- β in microglia in a TLR3-dependent manner^{34,84}. In astrocytes, cellular activities such as inhibiting high levels of furin-like protease activity contribute to a reduced susceptibility to the avirulent WNV-MAD78 infection⁸⁵. WNV infection in CNS cells also triggers the secretion of chemokines, which further facilitates immune cells to cross the BBB. For example, WNV-specific CXCR3⁺CD8⁺ T cells preferred to move into the cerebellum, where WNV-infected GCNs expressed a high grade of CXCL10 to clear virus⁸⁶. Accordingly, the CXCL10-deficient mice had decreased CD8⁺ T cell infiltration and increased viral load in the brain⁸⁷. Likewise, the expression of chemokine receptor CCR5 and its ligand CCL5 was prominently upregulated by WNV infection in the CNS. CCR5 has been implicated for the recruitment of leukocytes (including CD4⁺ and CD8⁺ T cells, natural killer cells, and macrophages) into the brain. CCR5-deficient mice rapidly succumbed to WNV infection and were not able to clear the virus in the brain during the time course of the disease⁸⁸.

Under normal physiological conditions, the integrity of the BBB restricts the infiltration of leukocytes and maintains the CNS as an immune-specialized compartment. Following systemic WNV infection, immune responses in the CNS are induced by infiltrating

inflammatory cells, including microglia/macrophages, neutrophils, and effector CD4⁺ and CD8⁺ T cells (Table 2)^{67,88–91}, and further infection in the CNS residential cells. Monocyte infiltration into the CNS is the hallmark of WNV encephalitis. After entry into the CNS, they differentiate into macrophages and microglia^{88,92}. Monocytes are presumably protective against WNV infection, as depletion of these cells increased mortality of mice infected with a neurotropic strain of WNV⁹³. However, inhibition of Ly6C^{hi} monocyte trafficking into the brain by anti-very late antigen-4 (anti-VLA-4) integrin antibody blockade at the time of observation of the first weight loss and leukocyte influx resulted in long-term survival in mice with lethal encephalitis⁹⁴. Although CCR2, a receptor expressed on Ly6C^{hi} inflammatory monocytes, is not directly involved in the recruitment of these cells from blood to the brain, it promotes peripheral monocytoysis during WNV infection, which is critical for ultimate accumulation of monocytes in the brain, and host protection⁹⁵. It was demonstrated that the CCR2 chemokine ligands CCL2 and CCL7 are involved in the monocytoysis and monocyte accumulation in the brain. The deficiency of CCL7 in mice leads to increased WNV load in the brain and enhanced mortality, suggesting a critical role of CCL7-mediated immune response in host protection⁹⁶. Furthermore, TLR7- and IL-23-dependent immune responses were known to mediate CD11b⁺ macrophage migration into the CNS and protect the host from lethal WNV infection⁴⁹. Neutrophils are another cell type detected in the CNS, but the role of these cells in WNV infection has yet to be elucidated. Evaluation of cell infiltrate in

cerebrospinal fluid from human cases of WNV meningitis and encephalitis showed high counts of neutrophils^{97,98}. Neutrophils were reported to display dual functions in WNV-infected mice. They could serve as reservoirs for virus replication in the periphery at early stage of infection, but are involved in viral clearance at the late stage of infection in the CNS⁴³. IL-22, a cytokine implicated in the modulation of the chemokine receptor CXCR2, is responsible for the recruitment of neutrophils⁹⁹. Finally, CD4⁺ T cells are required for the clearance of WNV from CNS and therefore mice survival, providing help for antibody responses, and sustaining WNV-specific CD8⁺ T cell responses in the CNS that enable viral clearance⁶⁷. They also have a direct antiviral role in the CNS by producing IFN- γ and IL-2 and have a potential for *in vivo* and *ex vivo* cytotoxicity¹⁰⁰. It has been demonstrated that IL-1R1 signaling modulates CD11c⁺ cell-mediated T cell reactivation and promotes virologic control during WNV infection within the CNS¹⁰¹. CD8⁺ T cells have an important function in clearing infection from the CNS and preventing viral persistence upon a low-dose WNV challenge^{68,102,103}. Nevertheless, CD8⁺ T cells are also involved in promoting CNS pathology following high doses of WNV infection^{104,105}. Thus, depending on the viral dosage, CD8⁺ T cells could be involved in both recovery and immunopathology in WNV infection. The effector function of T cells to control virus replication and eliminate the infection is directed through the production of cytokines, including IFN- γ , or direct killing of infected cells through secretion of perforin and signaling through Fas to -Fas ligand, or TNF-related apoptosis-inducing ligand (TRAIL)-dependent pathways^{68,102,103}. RLR-mediated innate signaling was reported to shape optimal CD8⁺ T cell activation and subsequent clearance of WNV from the CNS¹⁰⁶. CD11b⁺CD45^{hi} infiltrating cells (macrophages) are the primary producers of

IL-1 β within the CNS. By using an *in vitro* BBB model, Durrant *et al.* have shown that IL-1 β promotes CXCR4-mediated CD8⁺ T lymphocyte adhesion to BMVE cells. Furthermore, inhibition of CXCR4 promotes T lymphocyte entry into the CNS parenchyma, and this increases viral clearance and ultimately improves survival and reduces viral loads¹⁰⁷. Thus, perivascular localization might hinder antiviral immune responses during WNV encephalitis.

Conclusions

In summary, following systemic WNV infection, immune responses in the periphery help to control virus dissemination, whereas CNS immunity is critical for the clearance of virus. WNV has been the leading cause of viral encephalitis in the US for more than a decade. Current efforts on drug development have been focused mostly on the inhibitors of virus replication. Results from animal studies will provide a better understanding of the mechanisms by which flaviviruses enter the brain and induce lethal encephalitis; they may also lead to the development of new strategies to prevent and treat WNV-induced encephalitis.

Competing interests

The authors declare that they have no competing interests.

Grant information

This work was supported in part by National Institutes of Health grant R01 AI099123 (TW).

I confirm that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Nash D, Mostashari F, Fine A, *et al.*: **The outbreak of West Nile virus infection in the New York City area in 1999.** *N Engl J Med.* 2001; **344**(24): 1807–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Centers for Disease Control and Prevention (CDC): **Laboratory-acquired West Nile virus infections—United States, 2002.** *MMWR Morb Mortal Wkly Rep.* 2002; **51**(50): 1133–5.
[PubMed Abstract](#)
- Charatan F: **Organ transplants and blood transfusions may transmit West Nile virus.** *BMJ.* 2002; **325**(7364): 566.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Centers for Disease Control and Prevention (CDC): **Possible West Nile virus transmission to an infant through breast-feeding—Michigan, 2002.** *MMWR Morb Mortal Wkly Rep.* 2002; **51**(39): 877–8.
[PubMed Abstract](#)
- Alpert SG, Ferguson J, Noël LP: **Intrauterine West Nile virus: ocular and systemic findings.** *Am J Ophthalmol.* 2003; **136**(4): 733–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hayes EB, O'Leary DR: **West Nile virus infection: a pediatric perspective.** *Pediatrics.* 2004; **113**(5): 1375–81.
[PubMed Abstract](#)
- Hincley AF, O'Leary DR, Hayes EB: **Transmission of West Nile virus through human breast milk seems to be rare.** *Pediatrics.* 2007; **119**(3): e666–71.
[PubMed Abstract](#) | [F1000 Recommendation](#)
- Petersen LR, Brault AC, Nasci RS: **West Nile virus: review of the literature.** *JAMA.* 2013; **310**(3): 308–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Carson PJ, Konewko P, Wold KS, *et al.*: **Long-term clinical and neuropsychological outcomes of West Nile virus infection.** *Clin Infect Dis.* 2006; **43**(6): 723–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Ou AC, Ratard RC: **One-year sequelae in patients with West Nile Virus encephalitis and meningitis in Louisiana.** *J La State Med Soc.* 2005; **157**(1): 42–6.
[PubMed Abstract](#)
- Cook RL, Xu X, Yablonsky EJ, *et al.*: **Demographic and clinical factors associated with persistent symptoms after West Nile virus infection.** *Am J Trop Med Hyg.* 2010; **83**(5): 1133–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sadek JR, Pergam SA, Harrington JA, *et al.*: **Persistent neuropsychological impairment associated with West Nile virus infection.** *J Clin Exp Neuropsychol.* 2010; **32**(1): 81–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Nolan MS, Podoll AS, Hause AM, *et al.*: **Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort.** *PLoS One.* 2012; **7**(7): e40374.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Patel H, Sander B, Nelder MP: **Long-term sequelae of West Nile virus-related illness: a systematic review.** *Lancet Infect Dis.* 2015; **15**(8): 951–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Sejvar JJ: **Clinical manifestations and outcomes of West Nile virus infection.** *Viruses.* 2014; **6**(2): 606–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

16. Weatherhead JE, Miller VE, Garcia MN, *et al.*: **Long-term neurological outcomes in West Nile virus-infected patients: an observational study.** *Am J Trop Med Hyg.* 2015; **92**(5): 1006–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Anastasiadou A, Kakoulidis I, Butel D, *et al.*: **Follow-up study of Greek patients with West Nile virus neuroinvasive disease.** *Int J Infect Dis.* 2013; **17**(7): e494–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Centers for Disease Control and Prevention (CDC): **West Nile virus transmission via organ transplantation and blood transfusion - Louisiana, 2008.** *MMWR Morb Mortal Wkly Rep.* 2009; **58**(45): 1263–7.
[PubMed Abstract](#)
19. Nett RJ, Kuehnert MJ, Ison MG, *et al.*: **Current practices and evaluation of screening solid organ donors for West Nile virus.** *Transpl Infect Dis.* 2012; **14**(3): 268–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Tilley PA, Fox JD, Lee B, *et al.*: **Screening of organ and tissue donors for West Nile virus by nucleic acid amplification—a three year experience in Alberta.** *Am J Transplant.* 2008; **8**(10): 2119–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Beasley DW, Li L, Suderman MT, *et al.*: **Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype.** *Virology.* 2002; **296**(1): 17–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Samuel MA, Diamond MS: **Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.** *J Virol.* 2006; **80**(19): 9349–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Wang T, Fikrig E: **Immunity to West Nile virus.** *Curr Opin Immunol.* 2004; **16**(4): 519–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Hayes EB, Komar N, Nasci RS, *et al.*: **Epidemiology and transmission dynamics of West Nile virus disease.** *Emerg Infect Dis.* 2005; **11**(8): 1167–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Byrne SN, Halliday GM, Johnston LJ, *et al.*: **Interleukin-1beta but not tumor necrosis factor is involved in West Nile virus-induced Langerhans cell migration from the skin in C57BL/6 mice.** *J Invest Dermatol.* 2001; **117**(3): 702–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Lim PY, Behr MJ, Chadwick CM, *et al.*: **Keratinocytes are cell targets of West Nile virus *in vivo*.** *J Virol.* 2011; **85**(10): 5197–201.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Welte T, Reagan K, Fang H, *et al.*: **Toll-like receptor 7-induced immune response to cutaneous West Nile virus infection.** *J Gen Virol.* 2009; **90**(Pt 11): 2660–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Kramer LD, Bernard KA: **West Nile virus infection in birds and mammals.** *Ann NY Acad Sci.* 2001; **951**: 84–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Diamond MS, Sitati EM, Friend LD, *et al.*: **A critical role for induced IgM in the protection against West Nile virus infection.** *J Exp Med.* 2003; **198**(12): 1853–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Brightman MW, Ishihara S, Chang L: **Penetration of solutes, viruses, and cells across the blood-brain barrier.** *Curr Top Microbiol Immunol.* 1995; **202**: 63–78.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Engelhardt B: **Development of the blood-brain barrier.** *Cell Tissue Res.* 2003; **314**(1): 119–29.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Arjona A, Foellmer HG, Town T, *et al.*: **Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion.** *J Clin Invest.* 2007; **117**(10): 3059–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Daniels BP, Holman DW, Cruz-Orengo L, *et al.*: **Viral pathogen-associated molecular patterns regulate blood-brain barrier integrity via competing innate cytokine signals.** *MBio.* 2014; **5**(5): e01476–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
34. Wang T, Town T, Alexopoulou L, *et al.*: **Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis.** *Nat Med.* 2004; **10**(12): 1366–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
35. Wang P, Dai J, Bai F, *et al.*: **Matrix metalloproteinase 9 facilitates West Nile virus entry into the brain.** *J Virol.* 2008; **82**(18): 8978–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
36. Sultana H, Neelakanta G, Foellmer HG, *et al.*: **Semaphorin 7A contributes to West Nile virus pathogenesis through TGF- β /Smad6 signaling.** *J Immunol.* 2012; **189**(6): 3150–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
37. Bhattacharyya S, Zagórska A, Lew ED, *et al.*: **Enveloped Viruses Disable Innate Immune Responses in Dendritic Cells by Direct Activation of TAM Receptors.** *Cell Host Microbe.* 2013; **14**(2): 136–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
38. Miner JJ, Daniels BP, Shrestha B, *et al.*: **The TAM receptor MerTK protects against neuroinvasive viral infection by maintaining blood-brain barrier integrity.** *Nat Med.* 2015; **21**(12): 1464–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
39. Lazear HM, Daniels BP, Pinto AK, *et al.*: **Interferon- λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier.** *Sci Transl Med.* 2015; **7**(284): 284ra59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
40. Roe K, Orillo B, Verma S: **West Nile virus-induced cell adhesion molecules on human brain microvascular endothelial cells regulate leukocyte adhesion and modulate permeability of the *in vitro* blood-brain barrier model.** *PLoS One.* 2014; **9**(7): e102598.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Dai J, Wang P, Bai F, *et al.*: **Icam-1 participates in the entry of west nile virus into the central nervous system.** *J Virol.* 2008; **82**(8): 4164–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Verma S, Lo Y, Chapagain M, *et al.*: **West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: Transmigration across the *in vitro* blood-brain barrier.** *Virology.* 2009; **385**(2): 425–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
43. Bai F, Kong KF, Dai J, *et al.*: **A paradoxical role for neutrophils in the pathogenesis of West Nile virus.** *J Infect Dis.* 2010; **202**(12): 1804–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
44. Wang S, Welte T, McGargill M, *et al.*: **Drak2 contributes to West Nile virus entry into the brain and lethal encephalitis.** *J Immunol.* 2008; **181**(3): 2084–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Hunsperger EA, Roehrig JT: **Temporal analyses of the neuropathogenesis of a West Nile virus infection in mice.** *J Neurovirol.* 2006; **12**(2): 129–39.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Samuel MA, Wang H, Siddharthan V, *et al.*: **Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis.** *Proc Natl Acad Sci U S A.* 2007; **104**(43): 17140–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Monath TP, Cropp CB, Harrison AK: **Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy.** *Lab Invest.* 1983; **48**(4): 399–410.
[PubMed Abstract](#)
48. Errett JS, Suthar MS, McMillan A, *et al.*: **The essential, nonredundant roles of RIG-I and MDA5 in detecting and controlling West Nile virus infection.** *J Virol.* 2013; **87**(21): 11416–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Town T, Bai F, Wang T, *et al.*: **Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing.** *Immunity.* 2009; **30**(2): 242–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
50. Fredericksen BL, Keller BC, Fornek J, *et al.*: **Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1.** *J Virol.* 2008; **82**(2): 609–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Katze MG, He Y, Gale M Jr: **Viruses and interferon: a fight for supremacy.** *Nat Rev Immunol.* 2002; **2**(9): 675–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Samuel MA, Diamond MS: **Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival.** *J Virol.* 2005; **79**(21): 13350–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Lazear HM, Pinto AK, Vogt MR, *et al.*: **Beta interferon controls West Nile virus infection and pathogenesis in mice.** *J Virol.* 2011; **85**(14): 7186–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Thackray LB, Shrestha B, Richner JM, *et al.*: **Interferon regulatory factor 5-dependent immune responses in the draining lymph node protect against West Nile virus infection.** *J Virol.* 2014; **88**(19): 11007–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Wang T, Scully E, Yin Z, *et al.*: **IFN-gamma-producing gamma delta T cells help control murine West Nile virus infection.** *J Immunol.* 2003; **171**(5): 2524–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Shrestha B, Wang T, Samuel MA, *et al.*: **Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection.** *J Virol.* 2006; **80**(11): 5338–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Welte T, Lamb J, Anderson JF, *et al.*: **Role of two distinct gammadelta T cell subsets during West Nile virus infection.** *FEMS Immunol Med Microbiol.* 2008; **53**(2): 275–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Fang H, Welte T, Zheng X, *et al.*: **gammadelta T cells promote the maturation of dendritic cells during West Nile virus infection.** *FEMS Immunol Med Microbiol.* 2010; **59**(1): 71–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Wang T, Gao Y, Scully E, *et al.*: **Gamma delta T cells facilitate adaptive immunity against West Nile virus infection in mice.** *J Immunol.* 2006; **177**(3): 1825–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Diamond MS, Shrestha B, Marri A, *et al.*: **B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus.** *J Virol.* 2003; **77**(4): 2578–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

61. Diamond MS, Shrestha B, Mehloph E, *et al.*: Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. *Viral Immunol.* 2003; 16(3): 259–78.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Roehrig JT, Staudinger LA, Hunt AR, *et al.*: Antibody prophylaxis and therapy for flavivirus encephalitis infections. *Ann N Y Acad Sci.* 2001; 951: 286–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
63. Mehloph E, Diamond MS: Protective immune responses against West Nile virus are primed by distinct complement activation pathways. *J Exp Med.* 2006; 203(5): 1371–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. Mehloph E, Whitby K, Oliphant T, *et al.*: Complement activation is required for induction of a protective antibody response against West Nile virus infection. *J Virol.* 2005; 79(12): 7466–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. Kulkarni AB, Müllbacher A, Blanden RV: Functional analysis of macrophages, B cells and splenic dendritic cells as antigen-presenting cells in West Nile virus-specific murine T lymphocyte proliferation. *Immunol Cell Biol.* 1991; 69(Pt 2): 71–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Liu Y, Blanden RV, Müllbacher A: Identification of cytolytic lymphocytes in West Nile virus-infected murine central nervous system. *J Gen Virol.* 1989; 70(Pt 3): 565–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Sitati EM, Diamond MS: CD4⁺ T-cell responses are required for clearance of West Nile virus from the central nervous system. *J Virol.* 2006; 80(24): 12060–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
68. Shrestha B, Diamond MS: Role of CD8⁺ T cells in control of West Nile virus infection. *J Virol.* 2004; 78(15): 8312–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
69. Lanteri MC, O'Brien KM, Purtha WE, *et al.*: Tregs control the development of symptomatic West Nile virus infection in humans and mice. *J Clin Invest.* 2009; 119(11): 3266–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
70. Graham JB, Da Costa A, Lund JM: Regulatory T cells shape the resident memory T cell response to virus infection in the tissues. *J Immunol.* 2014; 192(2): 683–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
71. Suthar MS, Ma DY, Thomas S, *et al.*: IPS-1 is essential for the control of West Nile virus infection and immunity. *PLoS Pathog.* 2010; 6(2): e1000757.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
72. Campbell GL, Marfin AA, Lanciotti RS, *et al.*: West Nile virus. *Lancet Infect Dis.* 2002; 2(9): 519–29.
[PubMed Abstract](#) | [Publisher Full Text](#)
73. Solomon T, Ooi MH, Beasley DW, *et al.*: West Nile encephalitis. *BMJ.* 2003; 326(7394): 865–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
74. Brien JD, Uhrlaub JL, Hirsch A, *et al.*: Key role of T cell defects in age-related vulnerability to West Nile virus. *J Exp Med.* 2009; 206(12): 2735–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
75. Richner JM, Gmyrek GB, Govero J, *et al.*: Age-Dependent Cell Trafficking Defects in Draining Lymph Nodes Impair Adaptive Immunity and Control of West Nile Virus Infection. *PLoS Pathog.* 2015; 11(7): e1005027.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
76. Quick ED, Leser JS, Clarke P, *et al.*: Activation of intrinsic immune responses and microglial phagocytosis in an ex vivo spinal cord slice culture model of West Nile virus infection. *J Virol.* 2014; 88(22): 13005–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
77. Shrestha B, Gottlieb D, Diamond MS: Infection and injury of neurons by West Nile encephalitis virus. *J Virol.* 2003; 77(24): 13203–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
78. Cho H, Shrestha B, Sen GC, *et al.*: A role for Ifit2 in restricting West Nile virus infection in the brain. *J Virol.* 2013; 87(15): 8363–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
79. Cho H, Proll SC, Szretter KJ, *et al.*: Differential innate immune response programs in neuronal subtypes determine susceptibility to infection in the brain by positive-stranded RNA viruses. *Nat Med.* 2013; 19(4): 458–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
80. Ramos HJ, Lanteri MC, Blahnik G, *et al.*: IL-1 β signaling promotes CNS-intrinsic immune control of West Nile virus infection. *PLoS Pathog.* 2012; 8(11): e1003039.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
81. Daffis S, Samuel MA, Suthar MS, *et al.*: Toll-like receptor 3 has a protective role against West Nile virus infection. *J Virol.* 2008; 82(21): 10349–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
82. Szretter KJ, Daffis S, Patel J, *et al.*: The innate immune adaptor molecule MyD88 restricts West Nile virus replication and spread in neurons of the central nervous system. *J Virol.* 2010; 84(23): 12125–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
83. Wang P, Arjona A, Zhang Y, *et al.*: Caspase-12 controls West Nile virus infection via the viral RNA receptor RIG-I. *Nat Immunol.* 2010; 11(10): 912–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
84. Town T, Jeng D, Alexopoulou L, *et al.*: Microglia recognize double-stranded RNA via TLR3. *J Immunol.* 2006; 176(6): 3804–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
85. Hussmann KL, Samuel MA, Kim KS, *et al.*: Differential replication of pathogenic and nonpathogenic strains of West Nile virus within astrocytes. *J Virol.* 2013; 87(5): 2814–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
86. Zhang B, Chan YK, Lu B, *et al.*: CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. *J Immunol.* 2008; 180(4): 2641–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
87. Klein RS, Lin E, Zhang B, *et al.*: Neuronal CXCL10 directs CD8⁺ T-cell recruitment and control of West Nile virus encephalitis. *J Virol.* 2005; 79(17): 11457–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
88. Glass WG, Lim JK, Cholera R, *et al.*: Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. *J Exp Med.* 2005; 202(8): 1087–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
89. Bréhin AC, Mouriès J, Frenkiel MP, *et al.*: Dynamics of immune cell recruitment during West Nile encephalitis and identification of a new CD19⁺B220⁺BST-2⁺ leukocyte population. *J Immunol.* 2008; 180(10): 6760–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
90. Lim JK, Obara CJ, Rivollier A, *et al.*: Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis. *J Immunol.* 2011; 186(1): 471–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
91. Sitati E, McCandless EE, Klein RS, *et al.*: CD40-CD40 ligand interactions promote trafficking of CD8⁺ T cells into the brain and protection against West Nile virus encephalitis. *J Virol.* 2007; 81(18): 9801–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
92. Getts DR, Terry RL, Getts MT, *et al.*: Ly6c⁺ “inflammatory monocytes” are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. *J Exp Med.* 2008; 205(10): 2319–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
93. Ben-Nathan D, Huitinga I, Lustig S, *et al.*: West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. *Arch Virol.* 1996; 141(3–4): 459–69.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Getts DR, Terry RL, Getts MT, *et al.*: Targeted blockade in lethal West Nile virus encephalitis indicates a crucial role for very late antigen (VLA)-4-dependent recruitment of nitric oxide-producing macrophages. *J Neuroinflammation.* 2012; 9: 246.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
95. Lim JK, Obara CJ, Rivollier A, *et al.*: Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis. *J Immunol.* 2011; 186(1): 471–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
96. Bardina SV, Michlmayr D, Hoffman KW, *et al.*: Differential Roles of Chemokines CCL2 and CCL7 in Monocytosis and Leukocyte Migration during West Nile Virus Infection. *J Immunol.* 2015; 195(9): 4306–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
97. Rawal A, Gavin PJ, Sturgis CD: Cerebrospinal fluid cytology in seasonal epidemic West Nile virus meningo-encephalitis. *Diagn Cytopathol.* 2006; 34(2): 127–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
98. Tyler KL, Pape J, Goody RJ, *et al.*: CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis. *Neurology.* 2006; 66(3): 361–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
99. Wang P, Bai F, Zenewicz LA, *et al.*: IL-22 signaling contributes to West Nile encephalitis pathogenesis. *PLoS One.* 2012; 7(8): e44153.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
100. Brien JD, Uhrlaub JL, Nikolich-Zugich J: West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection. *J Immunol.* 2008; 181(12): 8568–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
101. Durrant DM, Robinette ML, Klein RS: IL-1R1 is required for dendritic cell-mediated T cell reactivation within the CNS during West Nile virus encephalitis. *J Exp Med.* 2013; 210(3): 503–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
102. Shrestha B, Pinto AK, Green S, *et al.*: CD8⁺ T cells use TRAIL to restrict West Nile virus pathogenesis by controlling infection in neurons. *J Virol.* 2012; 86(17): 8937–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
103. Shrestha B, Samuel MA, Diamond MS: CD8⁺ T cells require perforin to clear West Nile virus from infected neurons. *J Virol.* 2006; 80(1): 119–29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

104. Szretter KJ, Daniels BP, Cho H, *et al.*: **2'-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivo.** *PLoS Pathog.* 2012; **8**(5): e1002698.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
105. Wang Y, Lobigs M, Lee E, *et al.*: **CD8⁺ T cells mediate recovery and immunopathology in West Nile virus encephalitis.** *J Virol.* 2003; **77**(24): 13323–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
106. Lazear HM, Pinto AK, Ramos HJ, *et al.*: **Pattern recognition receptor MDA5 modulates CD8⁺ T cell-dependent clearance of West Nile virus from the central nervous system.** *J Virol.* 2013; **87**(21): 11401–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
107. Durrant DM, Daniels BP, Klein RS: **IL-1R1 signaling regulates CXCL12-mediated T cell localization and fate within the central nervous system during West Nile Virus encephalitis.** *J Immunol.* 2014; **193**(8): 4095–106.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Anna Papa**

Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

Competing Interests: No competing interests were disclosed.

2. **Giorgio Palù**

Department of Molecular Medicine, University of Padova, Padova, Italy

Competing Interests: No competing interests were disclosed.

3. **Sebastian Ulbert**

Department of Immunology, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research